Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system

International Journal of Pharmaceutics

Volumn 436, Issue 1-2, 2012, Pages 32-40

  Park, Chun Woong ^a,b   Son, Dao Danh ^a   Kim, Ju Young ^a   Oh, Tack Oon ^a   Ha, Jung Myung ^a   Rhee, Yun Seok ^c   Park, Eun Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b Chungbuk National University   (South Korea)

^c Gyeongsang National University   (South Korea)

Author keywords

Bioavailability; Galantamine; In vitro and in vivo characteristics; Skin permeation rate; Transdermal patch

Indexed keywords

GALANTAMINE; OLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; EXPERIMENTAL RABBIT; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SKIN PERMEABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH;

ADHESIVES; ADMINISTRATION, CUTANEOUS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; GALANTAMINE; MALE; OLEIC ACID; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SKIN ABSORPTION; TRANSDERMAL PATCH;

EID: 84865282045     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.06.057     Document Type: Article

References (35)

1. B.J. Aungst Structure/effect studies of fatty acid isomers as skin penetration enhancers and skin irritants Pharm. Res. 6 1989 244 247
2. B.W. Barry Novel mechanisms and devices to enable successful transdermal drug delivery Eur. J. Pharm. Sci. 14 2001 101 114
3. J. Bastida, F. Viladomat, J.M. Llabres, C. Codina, M. Feliz, and M. Rubiralta Alkaloids from Narcissus confusus Phytochemistry 26 1987 1519 1524
4. I. Benedek, and L.J. Heymans Pressure-Sensitive Adhesives Technology 1997 Marcel Dekker New York, USA
5. P. Chedgzoy, G. Winckle, and C.M. Heard Triclosan: release from transdermal adhesive formulations and in vitro permeation across human epidermal membranes Int. J. Pharm. 235 2002 229 236
6. E. Demirtürk, and L. Öner In vitro-in vivo correlations FABAD J. Pharm. Sci. 28 2003 175 227
7. H. Geerts, P.O. Guillaumat, C. Grantham, W. Bode, K. Anciaux, and S. Sachak Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits Brain Res. 1033 2005 186 193
8. D.P. Gondaliya, and K. Pundarikakshudu Enhanced transdermal permeation of bupropion hydrochloride by chemical modification Indian J. Pharm. Sci. 65 2003 671 674
9. N.T. Hai, J. Kim, E.S. Park, and S.C. Chi Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine Int. J. Pharm. 357 2008 55 60
10. M. Heinrich, and H. Lee Teoh Galanthamine from snowdrop - the development of a modern drug against Alzheimer's disease from local Caucasian knowledge J. Ethnopharmacol. 92 2004 147 162
11. Hille, T.; Hoffmann, H.-R.; Kreh, M.; Matusch, R.; 1999. Process for isolating galantamine. U.S. Patent 5,877,172.
12. Hille, T.; Hoffmann, H.-R.; Kreh, M.; Matusch, R.; 2003a. Process for isolating galantamine. U.S. Patent 6,573,376.
13. Hille, T.; Hoffmann, H.-R.; Kreh, M.; Matusch, R.; 2003b. Process for the isolation of galanthamine. U.S. Patent 6,617,452.
14. Hsu, T.-M.; Jacobson, E.C.; Luo, E.C.; 2002. Transdermal and topical administration of drugs for the treatment of alzheimer's disease using basic enhancers. U.S. Patent 0,192,243.
15. G.M. Janssen, J.B.A. Thijssen, and W.L.M. Verluyten Synthesis of 3H-, 14C-, and stable-isotope-labelled galantamine J. Labelled Compd. Radiopharm. 45 2002 841 855
16. A.K. Leonard, A.P. Sileno, G.C. Brandt, C.A. Foerder, S.C. Quay, and H.R. Costantino In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo Int. J. Pharm. 335 2007 138 146
17. H.Y. Li, G.E. Ma, Y. Xu, and S.H. Hong Alkaloids of Lycoris guangxiensis 1 Planta Med. 53 1987 259 261
18. S. Lilienfeld Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease CNS Drug Rev. 8 2002 159 176
19. M. Miyajima, A. Koshika, J. Okada, and i.M. Ikeda Effect of polymer/basic drug interactions on the two-stage diffusion-controlled release from a poly(-lactic acid) matrix J. Control. Release 61 1999 295 304
20. J. Monbaliu, T. Verhaeghe, B. Willems, W. Bode, K. Lavrijsen, and W. Meuldermans Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species Arzneimittelforschung. 53 2003 486 495
21. A. Naik, L.A.R.M. Pechtold, R.O. Potts, and R.H. Guy Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans J. Control. Release 37 1995 299 306
22. D.K. Parikh, and T.K. Ghosh Feasibility of transdermal delivery of fluoxetine AAPS PharmSciTech 6 2005 E144 E149
23. D. Prvulovic, H. Hampel, and J. Pantel Galantamine for Alzheimer's disease Expert Opin. Drug Metab. Toxicol. 6 2010 345 354
24. M.A. Raskind, E.R. Peskind, T. Wessel, and W. Yuan Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group Neurology 54 2000 2261 2268
25. Y.S. Rhee, S.Y. Kwon, C.W. Park, N.Y. Choi, W.J. Byun, S.C. Chi, and E.S. Park Characterization of monolithic matrix patch system containing tulobuterol Arch. Pharm. Res. 31 2008 1029 1034
26. L.J. Scott, and K.L. Goa Galantamine: a review of its use in Alzheimer's disease Drugs 60 2000 1095 1122
27. G. Small, and B. Dubois A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch Curr. Med. Res. Opin. 23 2007 2705 2713
28. J.J. Sramek, E.J. Frackiewicz, and N.R. Cutler Review of the acetylcholinesterase inhibitor galanthamine Expert Opin. Investig. Drugs 9 2000 2393 2402
29. H.S. Tan, and W.R. Pfister Pressure-sensitive adhesives for transdermal drug delivery systems Pharm. Sci. Technol. Today 2 1999 60 69
30. P. Tariot Current status and new developments with galantamine in the treatment of Alzheimer's disease Expert Opin. Pharmacother. 2 2001 2027 2049
31. M.S. Tian, L.S. Li, S. Liang, and Z. Hong-Yan Improvement of detection limit in HPLC determination of galantamine in plasma Chin. J. New Drugs 2003 10
32. M. Traykova, T. Traykov, V. Hadjimitova, D. Krikorian, S. Parushev, P. mechkarova, and N. Bojadgieva Galantamine and galantamine hydrobromide as scavengers of hydroxyl radicals C. R. Acad. Bulg. Sci. 56 2003 87 90
33. V.I. Turiiski, A.D. Krustev, V.N. Sirakov, and D.P. Getova In vivo and in vitro study of the influence of the anticholinesterase drug galantamine on motor and evacuative functions of rat gastrointestinal tract Eur. J. Pharmacol. 498 2004 233 239
34. M. Yasunori, K. Takemasa, and S. Kenji Diffusion of drugs in acrylic-type pressure-sensitive adhesive matrix. II. Influence of interaction J. Control. Release 18 1992 113 114
35. L. Zhao, Y. Li, L. Fang, Z. He, X. Liu, L. Wang, Y. Xu, and C. Ren Transdermal delivery of tolterodine by O-acylmenthol: in vitro/in vivo correlation Int. J. Pharm. 374 2009 73 81